Is ENvue Medical going out of business?

ENvue Medical, Inc. (FEED) Fundamentals

A quick summary of the latest filed figures while the full analysis loads.

ENvue Medical, Inc. (FEED) scores 12 out of 100 on fundamentals, Distressed / Caution, based on SEC filing data.

Leading signal: Shares dilution YoY: 1657.74% (YoY)

Five questions, kept separate

Survival - Critical

Under 1 mo of estimated runway from 2026-06-30, based on $1.1M of cash and short-term investments against $20.8M of annual burn. A disclosed filing event caps this reading; Event Risk carries the detail.

Business quality - Pre-commercial

Operating margins cannot grade a pipeline; Survival and clinical evidence remain the relevant lenses here.

Trajectory - Clinical progress unavailable

Fundamentals can show funding and burn, but not whether the clinical pipeline is advancing.

Valuation - Demanding

24.9% net-cash backing support a demanding pre-commercial Valuation assessment.

Event risk - Critical event risk

Going-Concern Warning is the decisive filing event; one adverse event family is active. It appears across 3 scanned filings. Favorable events are shown separately and do not offset adverse risk.

What the rules read

• Shares dilution YoY: 1657.74% (YoY)
• FCF margin: -1080.37%
• Debt / Equity: -0.03x (Net Cash)
• ROIC: -86.30%
• Filing event risk: Going-Concern Warning (-8 pts)
• Cash Runway (years): 0.05y
• Revenue CAGR (3Y): 50.29%
• R&D intensity: 62.25%
• Return on Assets: -53.22%
• Cash Burn Deceleration: -344.77% QoQ improvement (Worsening)
• Revenue Quality: Quality concerns (DSO +21d, Rev +-52%)
• Price / Sales: 1.8x (see Valuation)

Read from filings through 2026-08-17.

Price as of 2026-09-07.